VWD is classified into three main types based on the nature of the vWF defect.

• Most common (approximately 70% of cases)
• Mechanism: Reduced quantity of normal vWF
• Inheritance: Autosomal dominant
• Severity: Usually mild to moderate
• vWF levels: 20-50% of normal

Clinical features:

• Mild to moderate bleeding symptoms
• Often undiagnosed until surgery or trauma
• Responds well to desmopressin

Approximately 25% of cases. These are further subdivided based on the specific functional defect:

Type 2A

• Mechanism: Defect in vWF multimerization (missing large multimers)
• Function: Impaired platelet binding
• Inheritance: Usually autosomal dominant
• Severity: Moderate

Type 2B

• Mechanism: Increased affinity for platelet receptor
• Function: Can cause thrombocytopenia (low platelets) due to platelet clumping
• Inheritance: Autosomal dominant
• Severity: Variable

Type 2M

• Mechanism: Defect in platelet binding (normal multimers)
• Function: Impaired adhesion despite normal multimer pattern
• Inheritance: Usually autosomal dominant
• Severity: Moderate

Type 2N

• Mechanism: Defect in factor VIII binding
• Function: Low factor VIII levels, mimicking hemophilia A
• Inheritance: Autosomal recessive
• Severity: Can be severe

• Rare (approximately 5% of cases)
• Mechanism: Virtually absent vWF
• Inheritance: Usually autosomal recessive
• Severity: Severe
• vWF levels: <10% of normal or undetectable

Clinical features:

• Severe bleeding from early childhood
• Often presents with significant bleeding episodes
• Does not respond well to desmopressin
• Requires factor concentrate replacement

A rare form not inherited but develops later in life:

• Associated with certain conditions (lymphoproliferative disorders, cardiovascular disorders, autoimmune diseases)
• May be associated with certain medications
• Usually improves when underlying condition is treated

VWD is caused by mutations in the VWF gene located on chromosome 12. Over 200 different mutations have been identified.

Type 1 and Most Type 2

• Autosomal dominant inheritance
• One affected parent has 50% chance of passing to each child
• Variable expression within families
• Some carriers may be asymptomatic

Type 3 and Some Type 2 (especially 2N)

• Autosomal recessive inheritance
• Both parents must carry one copy of the gene
• If both parents are carriers, each child has 25% chance of having severe disease

• Family history: Having a family member with VWD increases risk
• Age: Symptoms may become more apparent with age
• Certain gene mutations: Specific VWF gene variants

• Some patients have no family history (de novo mutations)
• May represent previously undiagnosed family members

The clinical presentation of VWD varies widely depending on type and severity.

Mucocutaneous Bleeding

• Easy bruising: Bruises with minimal trauma
• Petechiae: Tiny red spots on skin
• Prolonged bleeding from cuts: Takes longer to stop bleeding
• Bleeding from gums: Especially after dental work
• Nosebleeds (epistaxis): Often frequent or prolonged

Gynecological Bleeding (Women)

• Heavy menstrual bleeding (menorrhagia): Most common symptom in women
• Prolonged menstrual periods (lasting >7 days)
• Passing large clots during periods
• Bleeding between periods
• Postmenopausal bleeding

Gastrointestinal Bleeding

• Bleeding from hemorrhoids
• Occult blood in stool (not visibly bloody)

• Prolonged bleeding after surgery or dental work: Often first sign in mild cases
• Bleeding after circumcision: May be first sign in males
• Postpartum bleeding: Excessive bleeding after childbirth
• Joint and muscle bleeding: Rare, more common in Type 3

Seek medical attention for:

• Unusual or excessive bleeding
• Bleeding that won't stop with pressure
• Bleeding into joints or muscles
• Severe headache or neurological symptoms
• Bleeding after surgery or dental work
• Any bleeding that seems disproportionate to the injury

Treatment for VWD is individualized based on type, severity, and specific bleeding episodes.

Desmopressin (DDAVP)

Mechanism: Stimulates release of vWF and factor VIII from endothelial cells

Administration:

• Intravenous (IV) infusion
• Nasal spray (Stimate®)
• Subcutaneous injection

Use:

• First-line treatment for Type 1 and most Type 2
• Effective for mild to moderate bleeding episodes
• Used prophylactically before surgery or dental work

Dosing:

• Usually 0.3 mcg/kg IV over 15-30 minutes
• Can repeat every 12-24 hours (tachyphylaxis may occur)

Side effects:

• Facial flushing
• Headache
• Nausea
• Fluid retention
• Rare: Hyponatremia (low sodium)

Contraindications:

• Type 2B (may worsen thrombocytopenia)
• Cardiovascular disease

von Willebrand Factor Concentrates

When needed:

• Type 3 patients (no response to DDAVP)
• Type 1 or 2 patients with poor response to DDAVP
• Major surgery or trauma
• Severe bleeding episodes

Products:

• Plasma-derived vWF/FVIII concentrates
• Recombinant vWF (recently available)
• Dosage based on vWF:RCo units and patient weight

Antifibrinolytic Agents

Mechanism: Inhibit breakdown of clots once formed

Medications:

• Tranexamic acid
• Aminocaproic acid

Use:

• Mild mucosal bleeding
• Heavy menstrual bleeding
• Dental procedures
• Can be used alone or with other treatments

Administration:

• Oral
• Topical (mouthwash for dental work)

Hormonal Therapies (for women)

• Combined oral contraceptives: Reduce menstrual bleeding
• Levonorgestrel IUD (Mirena®): Very effective for heavy bleeding
• Progestins: Oral or injectable

Fibrin Sealants

• Used topically for local bleeding
• Particularly useful in surgery

For Minor Bleeding

• First aid (pressure, ice)
• Antifibrinolytic agents
• DDAVP for responsive types

For Major Bleeding/Surgery

• DDAVP (if responsive)
• vWF concentrate
• Antifibrinolytics as adjunct
• Close monitoring

For Heavy Menstrual Bleeding

• Hormonal therapies
• Antifibrinolytics
• DDAVP
• Iron supplementation if anemic

At Healers Clinic Dubai, we offer integrative approaches to support patients with VWD.

Constitutional Approach

A constitutional remedy is selected based on complete symptom picture:

• Bleeding tendencies and modalities
• Physical symptoms
• Mental/emotional characteristics
• General constitution

Commonly Considered Remedies

• Arnica: Bruising, trauma-related bleeding
• Phosphorus: Easy bleeding, bruising, gum bleeding
• Lachesis: Purple/bluish discoloration, clotting issues
• Crotalus horridus: Severe bleeding tendencies
• Ferrum phosphoricum: Early bleeding, inflammation
• China (Cinchona): Weakness after blood loss

Dosha Assessment

• Evaluation of constitutional type
• Assessment of blood tissue (Rakta) quality

Treatment Approaches

• Dietary recommendations to support blood health
• Herbal support for circulation
• Lifestyle guidance
• Stress management

• Iron supplementation if deficient (common with heavy bleeding)
• Vitamin C for blood vessel health
• Vitamin K for clotting (in consultation with doctor)
• Balanced nutrition for overall health

All integrative treatments should complement, not replace, conventional medical management. Patients should:

• Never stop conventional treatments without medical supervision
• Inform all healthcare providers about all treatments
• Work with qualified practitioners

• Normal life expectancy with proper management
• Quality of life generally good with appropriate treatment

• VWD is a chronic condition requiring ongoing management
• Most patients live normal, active lives
• Bleeding episodes can be prevented or minimized with treatment
• Most serious complications are rare with proper care

With proper treatment, complications are uncommon:

• Chronic anemia from frequent bleeding
• Joint damage from bleeding (rare)
• Post-surgical bleeding complications
• Complications from blood products (historical, now rare)

Von Willebrand disease (VWD) is the most common inherited bleeding disorder, affecting approximately 1% of the population. It is caused by a deficiency or dysfunction of von Willebrand factor (vWF), a protein essential for blood clotting. The condition leads to prolonged bleeding from mucous membranes, easy bruising, heavy menstrual bleeding, and other bleeding manifestations.

No, von Willebrand disease is a separate disorder from hemophilia, though they share some features. Hemophilia A is caused by deficiency of factor VIII, while VWD is caused by deficiency/dysfunction of von Willebrand factor. However, some types of VWD (Type 2N) affect factor VIII levels and can mimic hemophilia A.

Type 1 and most Type 2 VWD are inherited as autosomal dominant traits, meaning a 50% chance of passing the gene to each child. Type 3 and some Type 2 are autosomal recessive, requiring both parents to carry the gene. Some cases arise from new mutations with no family history.

There is currently no cure for VWD, but it can be effectively managed with appropriate treatment. Most patients with VWD can lead normal, healthy lives with proper management. Treatment focuses on preventing and treating bleeding episodes.

Treatment depends on the type and severity:

• Desmopressin (DDAVP): First-line for Type 1 and most Type 2
• von Willebrand factor concentrates: For Type 3 or when DDAVP ineffective
• Antifibrinolytic agents: For mucosal bleeding
• Hormonal therapies: For heavy menstrual bleeding in women

No, NSAIDs like aspirin and ibuprofen should generally be avoided as they impair platelet function and can increase bleeding risk. Acetaminophen (Tylenol) is generally safe for pain relief. Always consult your doctor before taking any new medications.

VWD is a lifelong condition, but the intensity of treatment varies:

• Many patients only need treatment during bleeding episodes or before procedures
• Some patients require ongoing prophylactic treatment
• Regular follow-up with a hematologist is important

Yes, women with VWD can have children, but pregnancy and delivery require careful planning. vWF levels often rise during pregnancy, but delivery may still require DDAVP or factor concentrate. Coordination between hematology and obstetrics is essential.

At Healers Clinic Dubai, we provide comprehensive VWD care including diagnostic testing, conventional treatment (DDAVP, factor replacement, antifibrinolytics), and integrative support through homeopathy and Ayurvedic medicine. Our approach is individualized to each patient's needs.

With proper management, von Willebrand disease is generally not dangerous. Most patients have mild symptoms that can be controlled with treatment. However, severe cases (Type 3) or uncontrolled bleeding can be serious, so proper diagnosis and treatment are important.

Q: What are the types of von Willebrand disease? A: There are three main types: Type 1 (partial quantitative deficiency, most common, mild), Type 2 (qualitative dysfunction, several subtypes 2A, 2B, 2M, 2N), and Type 3 (complete quantitative deficiency, rare, severe). Each type has different treatment approaches.

Q: How is von Willebrand disease diagnosed? A: Diagnosis involves blood tests measuring von Willebrand factor antigen (vWF:Ag), vWF activity (ristocetin cofactor), and factor VIII levels. Additional tests may include vWF multimer analysis to identify specific subtypes. Testing may need to be repeated as levels can fluctuate.

Q: What triggers bleeding in von Willebrand disease? A: Bleeding is typically triggered by trauma, surgery, dental procedures, or menstruation. Mucosal bleeding (nose, gums, intestines) is common because vWF helps platelets adhere to blood vessel walls. The severity of bleeding correlates with vWF levels.

Q: Can von Willebrand disease skip generations? A: Yes, particularly with Type 1 (autosomal dominant with variable expression). A parent may have very mild symptoms while a child has more significant bleeding. Genetic testing can help identify affected family members.

Q: What is the DDAVP challenge test? A: This test determines if a patient will respond to desmopressin (DDAVP). Baseline blood tests are taken, DDAVP is administered, and blood tests are repeated to measure the response. This helps guide treatment decisions.

Q: Are there dietary restrictions with von Willebrand disease? A: No specific diet is required, but it's advisable to avoid NSAIDs (aspirin, ibuprofen) and limit alcohol. Foods rich in vitamin K (leafy greens) are not restricted as they don't affect vWF. Good nutrition supports overall vascular health.

Q: Can I play sports with von Willebrand disease? A: Most patients can participate in many activities. Contact sports should be avoided as bleeding from injuries can be significant. Swimming, walking, yoga, cycling, and dancing are good options. Discuss activities with your hematologist.

Q: What should I do before surgery or dental work? A: Inform your healthcare providers about your condition. Preoperative evaluation by a hematologist is important. Treatment with DDAVP or vWF concentrate may be needed before procedures. Close monitoring during and after procedures is essential.

Q: How does von Willebrand disease affect women specifically? A: Women often have more significant symptoms due to menstrual bleeding and childbirth. Heavy menstrual bleeding is common and may require hormonal treatments. Pregnancy may temporarily improve vWF levels but delivery requires planning. Many women are first diagnosed due to gynecological bleeding problems.

Q: What is the role of homeopathy in von Willebrand disease? A: Homeopathy provides constitutional support and may help with overall wellbeing, recovery from bleeding episodes, and energy levels. Individualized remedies are selected based on complete symptom presentation. Homeopathy is complementary to, not a replacement for, conventional treatment.